Skip to main content
. 2012 Apr;4(2):85–101. doi: 10.1177/1756287212441234

Figure 4.

Figure 4.

Persistency with zoledronic acid (ZOL) treatment was associated with a lower monthly rate of skeletal-related events in patients with bone metastases from solid tumors. Reproduced with permission from Hatoum et al. [2008]. © 2008 American Cancer Society.